Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
Nat Med
.
2024 Apr 22.
doi: 10.1038/s41591-024-03006-6.
Online ahead of print.
Authors
Deidre Wilkins
1
,
Yuan Yuan
2
,
Yue Chang
2
,
Anastasia A Aksyuk
2
,
Beatriz Seoane Núñez
3
,
Ulrika Wählby-Hamrén
4
,
Tianhui Zhang
5
,
Michael E Abram
2
,
Amanda Leach
6
,
Tonya Villafana
7
,
Mark T Esser
7
Affiliations
1
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA. deidre.wilkins@astrazeneca.com.
2
Translational Medicine, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
3
Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Madrid, Spain.
4
Clinical Pharmacology & Quantitative Pharmacology, R&D, AstraZeneca, Gothenburg, Sweden.
5
Data Sciences and Quantitative Biology, R&D, AstraZeneca, Gaithersburg, MD, USA.
6
Clinical Development, Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
7
Vaccines & Immune Therapies, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
PMID:
38649782
DOI:
10.1038/s41591-024-03006-6
No abstract available
Publication types
Published Erratum